【作者】 陈占红； 黄健； 曹文明； 邵喜英； 黄平； 蔡菊芬； 楼彩金； 叶魏武； 王晓稼；

【Author】 CHEN Zhan-hong,HUANG Jian,CAO Wen-ming,et al. (Zhejiang Cancer Hospital,Hangzhou 310022,China)

【机构】 浙江省肿瘤医院；

【摘要】 [目的]观察重组人红细胞生成素(rhEPO)对晚期乳腺癌化疗所致贫血的防治疗效。[方法]选择60例以多西紫杉醇为主的联合或单药化疗方案所致晚期乳腺癌贫血的患者(血红蛋白Hb≤110g/L,或化疗后Hb降低≥20g/L),随机分为两组,治疗组30例原方案化疗结束后48h皮下注射rhEPO4 0000 IU/周,连用8周。对照组30例不给予rhEPO治疗,均服生血宁片2片/次,3次/d,连续8周。[结果]对照组随化疗周期贫血程度上升,而EPO治疗可以明显减少化疗所致的各项血液学指标下降程度(P<0.05)。8周内EPO治疗组完成化疗总周期数为78个周期,对照组为64个周期,化疗完成率分别为86.7%和73.6%,两组差异有统计学意义(P=0.003);EPO治疗组有3.3%(1/30)患者需要输血,对照组有27.6%(8/29)患者需要输血,两组之间差异有统计学意义(x~2=4.96,P=0.026)。[结论]EPO对以多西紫杉醇为主的联合或单药化疗方案所致晚期乳腺癌贫血有一定疗效,维持Hb水平,减少输血要求,为顺利完成化疗提供有力的保障。更多还原

【Abstract】 [Purpose]To investigate the efficacy of recombinant human erythropoietin(rhEPO) therapy for chemotherapy-induced anemia in patients with advanced breast cancer.[Methods]A total of 60 patients with advanced breast cancer who treated with docetaxel-based combination or single-agent chemotherapyinduced anemia(hemoglobin≤110g/L,or reduced after chemotherapy≥20g/L) were collected in this study. Thirty patients were treated with rhEPO(rhEPO 4 0000 IU subcutaneous injection,48h after the end of the chemotherapy/per week,totally 8 weeks),30 patients were treated with Shengxuening(2 tablets tid for 8 weeks) as control group.[Results]There were significant difference in the degree of chemotherapy-induced hematological between the rhEPO group and control group(P<0.05).The total chemotherapy cycle within 8 weeks was 78 cycles in rhEPO group and 64 cycles in control group respectively.The rate of chemotherapy completion was 86.7%and 73.6%in the rhEPO group and control group,respectively(P=0.003).The proportion of transfusion in rhEPO group was lower than that in control group(3.3%vs 27.6%,P=0.026).[Conclusions] The efficacy of rhEPO on the docetaxel-based combination or single-agent chemotherapy-induced anemia in patients with advanced breast cancer is positive,especially in maintaining the Hb level,reducing transfusion requirements,and providing effective protection for the completion of chemotherapy.更多还原